Skip to main content
SpringerLink
Log in

Chemotherapy in Adult CNS Tumors

  • Chapter
Combined Modality Therapy of Central Nervous System Tumors

Part of the book series: Medical Radiology ((Med Radiol Radiat Oncol))

  • 175 Accesses

Abstract

Historically, chemotherapy has played a limited role in the multidisciplinary treatment of adult patients with CNS tumors. However, as we begin the twentyfirst century, a number of new cytotoxic and cytostatic drugs have entered the clinical arena. These drugs are the direct result of scientific research which has led to a better understanding of: (1) the molecular biology of CNS tumors (signal transduction/ growth factors, mechanisms of glial cell invasion, angiogenesis), (2) mechanisms of tumor cell resistance, and (3) novel delivery systems. In addition to novel therapeutics, a more rigorous paradigm of clinical research has evolved with multidisciplinary participation. The more rigorous design of current and future clinical trials with clinically meaningful end points that account for cytostatic as well as cytotoxic drug properties are major accomplishments. In addition, an appreciation of the importance of brain tumor histologic subtypes and important prognostic variables will allow for more efficient and reliable testing of these new agents. In summary, scientific progress, improved clinical trial design, and novel therapeutics will give the neurooncologist of the twenty-first century an armamentarium of therapeutics that will complement the advances in surgery and radiation therapy in the pursuit of improving quality of life and survival of patients with CNS tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Allen J (1991) Controversies in the management of intracranial germ cell tumors. Neurol Clin 9(2): 441-452

    PubMed  CAS  Google Scholar 

  • Allen J, Bosl G, Walker R, et al. (1985) Chemotherapy trials in recurrent primary intracranial germ cell tumors. J Neurooncol 3(2): 147-152

    Article  PubMed  CAS  Google Scholar 

  • Avgeropoulos N and Batchelor T (1999) New treatment strategies for malignant gliomas. Oncologist 4(3): 209-224

    PubMed  CAS  Google Scholar 

  • Baltuch G, Shenouda G, Langleben A, et al. (1993) High dose tamoxifen in the treatment of recurrent high grade glioma: a report of clinical stabilization and tumour regression. Can J Neurol Sci 20(2): 168-170

    PubMed  CAS  Google Scholar 

  • Belanich M., Pastor M, Randall T, et al. (1996) Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 56(4): 783-788

    PubMed  CAS  Google Scholar 

  • Brandes A, Ermani M, Turazzi S, et al. (1999) Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study. J Clin Oncol 17(2): 645-650

    PubMed  CAS  Google Scholar 

  • Brem H and Lawson H (1999) The development of new brain tumor therapy utilizing the local and sustained delivery of chemotherapeutic agents from biodegradable polymers. Cancer 86(2): 197-199

    Article  PubMed  CAS  Google Scholar 

  • Brem H., Piantadosi S, Burger P, et al. (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas, The Polymer-brain Tumor Treatment Group. Lancet 345(8956): 1008-1012

    Article  PubMed  CAS  Google Scholar 

  • Brock C, Newland E, Wedge S, et al. (1998) Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 58(19): 4363-4367

    PubMed  CAS  Google Scholar 

  • Burger P, Vogel F, Green S, et al. (1985) Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer. 56(5): 1106-1111

    Article  PubMed  CAS  Google Scholar 

  • Burton E and Prados M (1999) New chemotherapy options for the treatment of malignant gliomas. Current Opinion in Oncology 11: 157-161

    Article  PubMed  CAS  Google Scholar 

  • Cahan M, Walter K, Colvin O, et al. (1994) Cytotoxicity of taxol in vitro against human and rat malignant brain tumors. Cancer Chemother Pharmacol 33(5): 441-444

    Article  PubMed  CAS  Google Scholar 

  • Cairncross J, Ueki K, Zlatesku M, et al. (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90(19): 1473-1479

    Article  PubMed  CAS  Google Scholar 

  • Chamberlain M and Kormanik P (1995) Salvage chemotherapy with paclitaxel for recurrent primary brain tumors. J Clin Oncol 13(8): 2066-2071

    PubMed  CAS  Google Scholar 

  • Chamberlain M and Kormanik P (1997) Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas. J Clin Oncol 15(12): 3427-3432

    PubMed  CAS  Google Scholar 

  • Chamberlain M and Kormanik P (1999) Salvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomas. Arch Neurol 56(6): 703-708

    Article  PubMed  CAS  Google Scholar 

  • Chang S, Kuhn J, Rizzo J, et al. (1998) Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J Clin Oncol 16(6): 2188-2194

    PubMed  CAS  Google Scholar 

  • Cokgor I., Friedman H and Friedman A (1999) Chemotherapy for adults with malignant glioma. Cancer Invest 17(4): 264-272

    Article  PubMed  CAS  Google Scholar 

  • Couldwell W, Antel J, Apuzzo M, et al. (1990) Inhibition of growth of established human glioma cell lines by modulators of the protein kinase-C system. J Neurosurg 73(4): 594-600

    Article  PubMed  CAS  Google Scholar 

  • Couldwell W, Hinton D, Surnock A, et al. (1996) Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin Cancer Res 2(4): 619-622

    PubMed  CAS  Google Scholar 

  • Couldwell W, Uhm J, Antel J, et al. (1991) Enhanced protein kinase C activity correlates with the growth rate of malignant gliomas in vitro. Neurosurgery 29(6): 880-887

    Article  PubMed  CAS  Google Scholar 

  • Dinapoli R, Brown L, Arusell R, et al. (1993) Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma. J Clin Oncol 11(7): 1316-1321

    PubMed  CAS  Google Scholar 

  • Dolan M and Pegg A (1997). O6-benzylguanine and its role in chemotherapy. Clin Cancer Res 3(6): 837-847

    PubMed  CAS  Google Scholar 

  • Eagan R and Scott M (1983) Evaluation of prognostic factors in chemotherapy of recurrent brain tumors. J Clin Oncol 1(1): 38-44

    PubMed  CAS  Google Scholar 

  • Eckhardt S, Rizzo J, Sweeney K, et al. (1999) Phase I and Pharmacologic Study of the Tyrosine Kinas Inhibitor SU101 in Patients with Advanced Solid Tumors. Journal of Clinical Oncology 17(4): 1095-1104

    PubMed  CAS  Google Scholar 

  • Fine H (1994) The basis for current treatment recommendations for malignant gliomas. J Neurooncol 20(2): 111-120

    Article  PubMed  CAS  Google Scholar 

  • Fine H, Dear K, Loeffler J, et al. (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71(8): 2585-2597

    Article  PubMed  CAS  Google Scholar 

  • Fine H (1997) A Phase II trial of the anti-angiogenic agen thalidomide, in patients with recurrent high-grade gliomas. Proceedings ASCO (16), abstract #1372, pp. 385a

    Google Scholar 

  • Fine R, Williams A, Jett P, et al. (1990) Tamoxifen potentiates the antitumor effect of vinblastine against instrinsically multi-drug resistant human renal carcinoma cell lines. Proc Am Assn Cancer Res 31: 359

    Google Scholar 

  • Friedman A, Cokgor I, Kerby T, et al. (1999a) [abstract] Phase II Treatment of Anaplastic Oligodendro-Glioma and Low Grad Glioma with Temodal. Fourth Annual Meeting of French Society Neuro-Oncology, November 17-21, abstract #70, pp. 310

    Google Scholar 

  • Friedman H, Kerby T, Fields S, et al. (1999b). Topotecan treatment of adults with primary malignant glioma. The Brain Tumor Center at Duke. Cancer 85(5): 1160-1165

    Article  PubMed  CAS  Google Scholar 

  • Friedman H, Cokgor I, Kerby T, et al. (1999c) Phase I Clinical Trials of Gliadel Plus CPT-11 or Temodal. Fourth Annual Meeting of the Society for Neuro-Oncology, November 17-21, abstract #73, pp 311

    Google Scholar 

  • Friedman H, Kokkinakis D, Pluda J, et al. (1998) Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. J Clin Oncol 16(11): 3570-3575

    PubMed  CAS  Google Scholar 

  • Friedman H, McClendon R, Kerby T, et al. (1998) DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16(12): 3851-3857

    PubMed  CAS  Google Scholar 

  • Friedman H, Petros W, Friedman A, et al. (1999d) Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17(5): 1516-1525

    PubMed  CAS  Google Scholar 

  • Grunberg S, Bertram M, McDermed J, et al. (1987) Treatment of astrocytoma with a 5-day cisplatin infusion. Cancer Drug Deliv 4(1): 47-53

    Article  PubMed  CAS  Google Scholar 

  • Heimberger A, Archer G, Friedman H, et al. (1999) Intratumoral Temozolomide via Bulk Flow Microinfusion is Efficacious Against Intracranial Glioma. Fourth Annual Meeting of the Society for Neuro-Oncology, November17-21, abstract #90, pp. 315

    Google Scholar 

  • Hei T, Piao C, Geard C, et al. (1994) Taxol and ionizing radiation: interaction and mechanisms. Int J Radiat Oncol Biol Phys 29(2): 267-271

    Article  PubMed  CAS  Google Scholar 

  • Hubbard J, Scheithauer B, Kispert D, et al. (1989) Adult cerebellar medulloblastomas: the pathological, radiographic, and clinical disease spectrum. J Neurosurg 70(4): 536-544

    Article  PubMed  CAS  Google Scholar 

  • Jaeckle K, Eyre H, Townsend J, et al. (1998) Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis- chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol 16(10): 3310-3315

    PubMed  CAS  Google Scholar 

  • Kida Y, Kobayashi T, Yoshida J, et al. (1986) Chemotherapy with cisplatin for AFP-secreting germ-cell tumors of the central nervous system. J Neurosurg 65(4): 470-475

    Article  PubMed  CAS  Google Scholar 

  • Klauber N, Parangi S, Flynn E, et al. (1997) Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 57(1): 81-86

    PubMed  CAS  Google Scholar 

  • Kristiansen K, Hagen S, Kollevold T, et al. (1981) Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: aprospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 47(4): 649-652

    Article  PubMed  CAS  Google Scholar 

  • Lederman G, Arbit E, Odaimi M, et al. (1998) Fractionated stereotactic radiosurgery and concurrent taxol in recurrent glioblastoma multiforme: a preliminary report. Int J Radiat Oncol Biol Phys 40(3): 661-666

    Article  PubMed  CAS  Google Scholar 

  • Lederman G, Arbit E, Odaimi M, et al. (1997) Recurrent glioblastoma multiforme: potential benefits using fractionated stereotactic radiotherapy and concurrent taxol. Stereotact Funct Neurosurg 69(1-4): 162-174

    Article  PubMed  CAS  Google Scholar 

  • Levin V and Prados M (1992) Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance. J Clin Oncol 10(5): 766-771

    PubMed  CAS  Google Scholar 

  • Levin V, Silver P, Hannigan J, et al. (1990) Superiority of postradiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 18(2): 321-324

    Article  PubMed  CAS  Google Scholar 

  • Longee D, Friedman H, Albright R, et al. (1990) Treatment of patients with recurrent gliomas with cyclophosphamide and vincristine. J Neurosurg 72(4): 583-588

    Article  PubMed  CAS  Google Scholar 

  • MacDonald D, Cascino T, Schold S, et al. (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7): 1277-1280

    PubMed  CAS  Google Scholar 

  • Manfedi J, Parness J and Horwitz S (1982) Taxol binds to cellular microtubules. J Cell Biol 94(3): 688-996

    Article  Google Scholar 

  • McClay E, Albright K, Jones J, et al. (1993) Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells. Cancer Res 53(7): 1571-1576

    PubMed  CAS  Google Scholar 

  • Menei P, Venier M, Gamelin E, et al. (1999) Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma: apilot study. Cancer 86(2): 325-330

    Article  PubMed  CAS  Google Scholar 

  • Nelson D, Nelson J, Davis D, et al. (1985) Survival and prognosis of patients with astrocytoma with atypical or anaplastic features. J Neurooncol 3(2): 99-103

    Article  PubMed  CAS  Google Scholar 

  • Nelson J, Tsukada Y, Schoenfeld D, et al. (1983) Necrosis as aprognostic criterion in malignant supratentorial, astrocytic gliomas. Cancer 52(3): 550-554

    Article  PubMed  CAS  Google Scholar 

  • Newlands E, Blackledge S, Slack J, et al. (1992) Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 65(2): 287-291

    Article  PubMed  CAS  Google Scholar 

  • O¡¯Brian C, Liskamp A, Soloman D, et al. (1985). Inhibition of protein kinase C by tamoxifen. Cancer Res 45(6): 2462-2465

    Google Scholar 

  • O¡¯Reilly S, Newlands E, Glaser M, et al. (1993) Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours [published erratum appears in Eur J Cancer 1993;29 A(10):1500]. Eur J Cancer 7: 940-942

    Google Scholar 

  • Osoba D (1999) Proceedings ASCO (18) abstract #541, pp. 191a

    Google Scholar 

  • Parness J, and Horwitz S (1981) Taxol binds to polymerized tubulin in vitro.¡± J Cell Biol 91(2 Pt 1): 479-487

    Article  PubMed  CAS  Google Scholar 

  • Patel S, Buckner J, Smithson W, et al. (1992) Cisplatin-based chemotherapy in primary central nervous system germ cell tumors. J Neurooncol 12(1): 47-52

    Article  PubMed  CAS  Google Scholar 

  • Pech I, Peterson K, Cairncross J (1998) Chemotherapy for Brain Tumors. Oncology 1(12) #4, 537-543

    Google Scholar 

  • Pollack I, Randall M, Kristofik M, et al. (1990a) Effect of tamoxifen on DNA synthesis and proliferation of human malignant glioma lines in vitro. Cancer Res 50(22): 7134-7138

    PubMed  CAS  Google Scholar 

  • Pollack I, Randall M, Kristofik M, et al. (1990b) Response of malignant glioma cell lines to activation and inhibition of protein kinase C-mediated pathways. J Neurosurg 73(1): 98-105

    Article  PubMed  CAS  Google Scholar 

  • Prados M, Schold S, Spence A, et al. (1996) Phase II study of paclitaxel in patients with recurrent malignant glioma. J Clin Oncol 14(8): 2316-2321

    PubMed  CAS  Google Scholar 

  • Prados M, Scott C, Curran W, et al. (1999) Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of radiation therapy oncology group protocols comparing survivalwith carmustine or PCV adjuvant chemotherapy [In Process Citation]. J Clin Oncol 17(11): 3389-3395

    PubMed  CAS  Google Scholar 

  • Reifenberger J, Reifenberger G, Liu L, et al. (1994) Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145(5): 1175-1190

    PubMed  CAS  Google Scholar 

  • Rothenberg M (1996) CPT-11: an original spectrum of clinical activity.¡± Semin Oncol 23(1 Suppl 3): 21-26

    Google Scholar 

  • Schering Plough Corporation study 194-122 (1999) (Personal Contact)

    Google Scholar 

  • Schiff P, Fant J, Horwitz S (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277(5698): 665-667

    Article  PubMed  CAS  Google Scholar 

  • Shaw E, Scheithauer W, O¡¯Fallon J, et al. (1992) Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg 76(3): 428-434

    Article  PubMed  CAS  Google Scholar 

  • Sheline G (1990) Radiotherapy for high grade gliomas. Int J Radiat Oncol Biol Phys 18(4): 793-803

    Article  PubMed  CAS  Google Scholar 

  • Soulie P, Raymond E, Brienza S, et al. (1997) Oxaliplatin: the first DACH platinum in clinical practice. Bull Cancer 84(6): 665-673

    PubMed  CAS  Google Scholar 

  • Stewart D, O¡¯Bryan R, Al-Sarraf M, et al. (1983) Phase II study of cisplatin in recurrent astrocytomas in adults: a Southwest Oncology Group Study. J Neurooncol 1(2): 145-147

    PubMed  CAS  Google Scholar 

  • Stuart N, Philip P, Harris A, et al. (1992) High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines. Br J Cancer 66(5): 833-839

    Article  PubMed  CAS  Google Scholar 

  • Stupp R, Ostermann S, Pica A, et al. (1999) Daily temozolomide and concomitant radiotherapy followed by adjuvant temozolomide for patients with newly diagnosed glioblastoma multiforme, a well tolerated and promising regimen. Thirteenth International Conference of Brain Tumor Researc and Therapy, Sapporo, Japan. October 4-6

    Google Scholar 

  • Terzis A, Thorsen F, Heese O, et al. (1997) Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro. Br J Cancer 75(12): 1744-1752

    Article  PubMed  CAS  Google Scholar 

  • Tishler R, Schiff P, Geard C, et al. (1992) Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 22(3): 613-617

    Article  PubMed  CAS  Google Scholar 

  • Trump D, Smith D, Ellis P, et al. (1992) High-dose oraltamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst 84(23): 1811-1816

    Article  PubMed  CAS  Google Scholar 

  • Valtonen S, Timonen U, Toivanen P, et al. (1997) Interstitial chemotherapy with carmustine-loaded polymers for high- grade gliomas: a randomized double-blind study. Neurosurgery 41(1): 44-49

    Article  PubMed  CAS  Google Scholar 

  • Vertosick F, Selker R, Pollack I, et al. (1992) The treatment of intracranial malignant gliomas using orally administered tamoxifen therapy: preliminary results in a series of ¡°failed¡± patients. Neurosurgery 30(6): 897-903

    Article  PubMed  Google Scholar 

  • Walker M, Alexander E, Hunt W, et al. (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49(3): 333-343

    Article  PubMed  CAS  Google Scholar 

  • Wong E, Hess K, Gleason M, et al. (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17(8): 2572

    PubMed  CAS  Google Scholar 

  • Yung A, Levin V, Albright R, et al. (1999a) Proceedings ASCO 18:abstract #532, pp. 139a

    Google Scholar 

  • Yung W, Jaeckle K, Kyritsis A, et al. (1999b) [abstract] A combination of Temozolomide and Interferon-A in Recurrent Malignant Gliomas, A Phase II Study. Fourth Annual Meeting of the Society for Neuro-Oncology, November, abstract #217, pp. 347

    Google Scholar 

  • Yung W, Prados M, Yaya-Tur R, et al. (1999c) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse [In Process Citation]. J Clin Oncol 17(9): 2762

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Steven O’Day
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Barbara Dykes
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, University of Southern California, Keck School of Medicine 1441 Eastlake Avenue, Room G356, Los Angeles, CA, 90033-0804, USA

    Zbigniew Petrovich MD, FACR (Professor and Chairman) (Professor and Chairman)

  2. Department of Radiation Oncology, Hahnemann University Hospital, Broad & Vine Sts., Mail Stop 200, Philadelphia, PA, 19102, USA

    Luther W. Brady MD (Hylda Cohn/ American Cancer Society Professor of Clinical Oncology and Professor) (Hylda Cohn/ American Cancer Society Professor of Clinical Oncology and Professor)

  3. Keck School of Medicine of the University of Southern California, Los Angeles, CA, 90033, USA

    Michael L. J. Apuzzo MD (Edwin M. Todd/Trent H. Wells, Jr. Professor of Neurological Surgery and Professor of Radiation Oncology) (Edwin M. Todd/Trent H. Wells, Jr. Professor of Neurological Surgery and Professor of Radiation Oncology)

  4. Department of Radiotherapy, Eberhard-Karls-Universität, Hoppe-Seyler-Strasse 3, 72076, Tübingen, Germany

    Michael Bamberg MD

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

O’Day, S., Dykes, B. (2003). Chemotherapy in Adult CNS Tumors. In: Petrovich, Z., Brady, L.W., Apuzzo, M.L.J., Bamberg, M. (eds) Combined Modality Therapy of Central Nervous System Tumors. Medical Radiology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56411-6_24

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-56411-6_24

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-00627-5

  • Online ISBN: 978-3-642-56411-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation